New combo therapy aims to cut treatment breaks for anal cancer patients
NCT ID NCT02701088
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new way of delivering radiation therapy (SIB-IMRT) together with standard chemotherapy (5-FU and Mitomycin-C) for people with locally advanced anal cancer. The goal is to see if this approach can improve tumor control and reduce the severe side effects that often force patients to take breaks from treatment. About 71 participants will be followed for up to a year to measure outcomes like tumor response, side effects, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-Fluorouracil and Mitomycin-C (chemotherapy drugs) plus a special type of radiation therapy (SIB-IMRT) that delivers different doses to different areas at the same time.
What this could lead to
If successful, this could offer a more effective and less toxic treatment for locally advanced anal cancer, potentially reducing the need for treatment breaks and improving quality of life.
What could go wrong
This is a Phase 2 trial with only 71 participants, so results may not apply to everyone. The combination may still cause significant side effects, and the long-term benefits are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED ANAL CANAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Léon Berard
Lyon, France
-
Centre Paul Strauss
Strasbourg, France
-
IUCT-Oncopole
Toulouse, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
-
Institut de Cancérologie de l'Ouest - Centre Paul Papin
Angers, France
-
Institut de cancérologie de l'Ouest
Saint-Herblain, 44805, France